

AD _____

Award Number: DAMD17-02-1-0328

TITLE: Modulation of VEGF Bioavailability in Breast Tumors by
Direct MMP Cleavage

PRINCIPAL INVESTIGATOR: Sunyoung Lee, Ph.D.
Luisa Iruela-Arispe, Ph.D.

CONTRACTING ORGANIZATION: University of California
Los Angeles, CA 90024-1406

REPORT DATE: May 2004

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

BEST AVAILABLE COPY

20040917 085

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE May 2004	3. REPORT TYPE AND DATES COVERED Annual Summary (16 Apr 2003 - 15 Apr 2004)	
4. TITLE AND SUBTITLE Modulation of VEGF Bioavailability in Breast Tumors by Direct MMP Cleavage			5. FUNDING NUMBERS DAMD17-02-1-0328	
6. AUTHOR(S) Sunyoung Lee, Ph.D. Luisa Iruela-Arispe, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of California Los Angeles, CA 90024-1406 E-Mail: sunyoung@ucla.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 Words) VEGF-A is one of the most relevant mediators of capillary morphogenesis during development and a key stimulator of tumor-induced angiogenesis. hVEGF-A exists in five forms, VEGF ₁₂₁ , VEGF ₁₄₅ , VEGF ₁₆₅ , VEGF ₁₈₉ , and VEGF ₂₀₅ , as a result of alternative splicing from a single gene. These various isoforms differ in their affinity for extracellular matrix (ECM) proteins(all except for VEGF ₁₂₁ bind to ECM components upon secretion) and regulate vascular density and patterning of vessels in vivo. ECM-binding mVEGF ₁₈₈ promotes ectopic filopodia extension and excess branching, while soluble mVEGF ₁₂₀ mouse embryo shows a reduction in vascular branching. We previously found that several MMPs cleave mVEGF ₁₆₄ , releasing bioactive VEGF fragment(mVEGF ₁₁₃). To further explore the relevance of this processing event, we generated an uncleavable form of mVEGF ₁₆₄ (mVEGFDDP). Xenografts tumors of T47D cells expressing mVEGF ₁₁₃ and mVEGFDDP showed different tumor growth kinetics and differential tumor vessel formation. mVEGFDDP tumors grew faster and bigger than wild-type VEGF tumors, followed by mVEGF ₁₁₃ tumors. Also, mVEGFDDP tumors showed excessive sprouting with long and thin vessels, while mVEGF ₁₁₃ tumors showed reduced vessel branching and density. Overall the data imply that VEGF may be processed extracellularly and this proteolysis might offer an important mode for extracellular regulation in addition to splicing events.				
14. SUBJECT TERMS VEGF, Angiogenesis, extracellular matrix, MMP			15. NUMBER OF PAGES 11	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	5
Key Research Accomplishments.....	8
Reportable Outcomes.....	9
Conclusions.....	10
References.....	11
Appendices.....	none

Introduction

VEGF-A is one of the most relevant mediators of capillary morphogenesis during development and a key stimulator of tumor-induced angiogenesis. hVEGF-A exists in five forms, VEGF₁₂₁, VEGF₁₄₅, VEGF₁₆₅, VEGF₁₈₉, and VEGF₂₀₅, as a result of alternative splicing from a single gene. These various isoforms differ in their affinity for extracellular matrix (ECM) proteins: all except for VEGF₁₂₁ bind to ECM components upon secretion. Also, recently Ruhrberg, C. and colleagues showed that the different isoforms regulate vascular density and patterning of vessels in vivo. ECM-binding mVEGF₁₈₈ promotes ectopic filopodia extension and excess branching, while soluble mVEGF₁₂₀ mouse embryo shows a reduction in vascular branching. We previously found that several MMPs cleave mVEGF₁₆₄, releasing a VEGF fragment similar to soluble mVEGF₁₂₀ that can still phosphorylate VEGFR2. We further explored the relevance of this processing event by developing an uncleavable form of mVEGF₁₆₄ and analyzing xenograft tumors of T47D cells expressing mVEGF₁₆₄, fully cleaved VEGF form and uncleavable VEGF form. Recent findings from our laboratory revealed that VEGF may be processed extracellularly and this proteolysis might offer an important mode for extracellular regulation of vascular expansion that is additional to splicing events.

Body – Results

1) Expression of different VEGF forms lead to different tumor kinetics

In our previous report, we communicated that VEGF can be processed by MMP3 releasing two fragments: a 16kDa and a 6kDa species. We have mapped the site of cleavage to aa 113. To assess whether this form was biologically active, we generated recombinant protein and evaluated VEGFR2 phosphorylation. Two forms were made: a) a protein that mimics VEGF after MMP-3 cleavage and b) a protein that cannot be cleaved by MMP-3 - this was accomplished by removing 10 aa in the cleavage region (mVEGF_{DDP}). Both the ~16kDa VEGF fragment (mVEGF₁₁₃) and uncleavable VEGF form (mVEGF_{DDP}) are functionally active as they phosphorylate VEGFR-2 in porcine aortic endothelial cells (Fig. 1).




Fig 1. PAE-KDR cells were incubated with purified mVEGF₁₆₄, VEGF₁₁₃, VEGF_{DDP}, VEGF₁₂₁ and VEGF₁₄₅. Phosphorylation of VEGFR-2 was examined by SDS-PAGE followed by immunoblotting with anti-phosphotyrosine antibody. PAE-KDR: porcine aortic endothelial cells stably expressing VEGFR-2. arrowhead indicates VEGFR-2

Given the importance of angiogenesis during tumor growth, we also investigated the effect of expression of different VEGF forms on tumor growth. T47D breast carcinoma cells stably expressing mVEGF₁₆₄, mVEGF₁₁₃ or mVEGF_{DDP} were injected into the back of nude mice subcutaneously. As shown in Fig. 2, tumors expressing mVEGF_{DDP} grew the biggest while tumors expressing mVEGF₁₁₃ grew the smallest.




Fig 2. Tumor size: mVEGF_{DDP} > control > mVEGF₁₆₄ > mVEGF₁₁₃. Tumors were harvested 5 weeks after injection of 10⁶ cells subcutaneously in the flank of the mouse.

2) No direct correlation between VEGF levels and tumor size

To explore reasons for the different tumor kinetics by T47D cells expressing different VEGF forms, we investigated 1) T47D cells growth kinetics in vitro and 2) the correlation between VEGF levels and tumor size. As shown in Fig. 3, expression of different VEGF forms did not affect T47D cells proliferation rate. Correlation between the levels of VEGF and tumor sizes was investigated by VEGF western analysis of tumor lysates (Fig. 4) and mouse VEGF ELISA of mice serum (Fig. 5). Our data showed that circulating level of VEGF did not correlate with tumor size.

cell number (x10000)




Fig 3. In vitro T47Ds proliferation assay. T47D cells and T47D cells stably expressing mVEGF₁₆₄, VEGF₁₁₃ and mVEGF_{DDP} were plated in 10 cm dishes. Cells were trypsinized and counted at days 2, 4, 6, 8, 10 and 12. Cell numbers were averaged after counting triplicated plates.

control 164 mVEGF
 Δ 109-118 113



Fig 4. VEGF levels in tumor lysates. Tumors were harvested from T47D xenografted mice and solubilized in lysis buffer. Lysates were analyzed by SDS-PAGE followed by immunoblotting by using VEGF antibody.




Fig. 5. VEGF levels in blood. Blood was drawn from the hearts of xenograft mice. VEGF levels from serum were determined by mVEGF ELISA kit (Oncogene, Boston, MA). Each bar represents an independent mouse. T47D: cells transfected with empty vector, mv1: cells transfected with mouse VEGF, DDP: transfected with uncleavable VEGF, 113: transfected with cleaved VEGF.

3) Different VEGF forms leads to differential vascular expansion

To investigate the effect of different VEGF forms on angiogenesis, tumor sections and tumor-surrounding skin of mice expressing different VEGF forms were stained with anti-PECAM antibody. Tumor vessels and skin vessels of mice injected with T47D/mVEGF₁₁₃ showed reduced vessel density with dilated vessel diameter while those of mice injected with T47D/mVEGF_{DDP} showed increased vessel density with excessive vessel sprouting (Fig. 6) that are reminiscent of vessel expansion patterns of mice embryos expressing mVEGF₁₂₀ or mVEGF₁₈₈ (Ruhrberg, C. et al, 2002).




Fig 6. Tumors and skin surrounding tumors were fixed in 1 % paraformaldehyde (PFA) overnight at 4 °C. Fixed tumors were sectioned at 200-um thickness using a Vibratome (Ted Pella; Redding, CA). Endothelial cells were detected with a rat anti-mouse CD31 Ab.

Key Research Accomplishments

In this Annual Summary Report II present the research accomplishments for the period of April 16, 2003 - April 15, 2004 under the Award number DAMD17-02-1-0328. This report addresses the research accomplishments with respect to the Statement of Work associated with specific Aims 2 : “to determine the relevance of released peptides to VEGF receptor signal transduction”.

Reportable Outcomes

1. Development of 293T and T47D (breast tumor) cell lines expressing mVEGF₁₁₃ and mVEGF_{DDP}.

2. Oral presentations based on selection from submitted abstracts

NAVBO Developmental Vascular Biology Workshop, Feb. 1-5, 2004, Asilomar, California

International Vascular Biology Meeting XIII, June 1-5, 2004, Toronto, Canada

Conclusions

These results demonstrate that VEGF may be processed extracellularly releasing bioactive fragments and that this proteolysis might offer an important mode for regulation on VEGF bioavailability. Furthermore, our findings underscore the relevance of VEGF-bound versus –soluble in eliciting valuable angiogenic responses.

References

- Bergers, G, Brekken, R, McMahon, G, Vu, TH, Itoh, T, Tamaki, K, Tanzawa, K, Thorpe, P, Itohara, S, Werb, Z and Hanahan, D. 2000. *Nat. Cell Biol.* Oct;2(10):737-744.
- Carmeliet, P and Collen, D. 2000. *Ann N Y Acad. Sci.* 902:249-262; discussion 262-4.
- Carpizo, D and Iruela-Arispe, ML. 2000. *Cancer and Metastasis Reviews.* 19:159-165.
- Dvorak, HF. 2000. *Semin. Perinatol.* 24:75-78.
- Ferrara, N. 2000. *Curr. Opin. Biotechnol.* 11:617-624.
- Ferrara, N, Chen, H, Davis-Smyth, T, Gerber, HP, Nguyen, TN, Peers, D, Chisholm, V, Hillan, KJ and Schwall, RH. 1998. *Nat. Med.* 4:336-340.
- Ferrara, N, Carver-Moore, K, Chen, H, Dowd, M, Lu, L, O'Shea, KS, Powell-Braxton, L, Hillan, KJ and Moore, MW. 1996. *Nature.* 380:439-442.
- Hanahan, D, and Weinberg, RA. 2000. *Cell.* 100: 57-70.
- Korpelainen, E and Alitalo, K. 1998. *Curr. Opin. Cell Biol.* 10:159-164.
- Sugihara T, Wadhwa R, Kaul S.C. and Mitsui Y. 1998. *J. Biol. Chem.* 273(30): 3033-3038
- Petrova, TV, Makinen, T and Alitalo, K. 1999. *Exp. Cell Res.* 253:117-130.
- Ruhrberg, C., Gerhardt, H., Golding, M., Watson, R., Sofia, I., Fujisawa, H., Betsholtz, C. and Shima, S. T. 2002 *Genes & Development* 16:2684-2880.
- Vu, TH, Shipley, JM, Bergers, G, Berger, JE, Helms, JA, Hanahan, D, Shapiro, SD, Senior, RM and Werb, Z. 1998 *Cell.* 93(3):411-22.
- Whitelock, JM, Murdoch, AD, Iozzo, RV and Underwood, PA. 1996. *J. Biol. Chem.* 271(17):10079-86.